Mouse model for ocular neovascularization

Details Mouse model for ocular neovascularization Mouse model for ocular neovascularization

2000-06-05

2002-11-12

Wilson, Michael C. (Department: 1632)

Multicellular living organisms and unmodified parts thereof and

Nonhuman animal

Transgenic nonhuman animal

C800S003000

Reexamination Certificate

active

06479729

ABSTRACT:

TECHNICAL FIELD OF THE INVENTION
This invention is related to the field of retinopathies, particularly those caused by neovascularization.
BACKGROUND OF THE INVENTION
New blood vessel formation or neovascularization (NV) is essential for normal eye development, but it can also cause severe ocular disease. In the retina, NV is associated with a number of disease processes, the most common of which is diabetic retinopathy, a major cause of new blindness in developed nations
1
. Occlusion of retinal vessels leading to retinal ischemia is a feature shared by most diseases in which retinal NV occurs. This observation led to the hypothesis that the development of retinal NV is stimulated by one or more angiogenesis factors released by ischemic retina
2, 3
. Substantial effort has been devoted to identifying the factor or factors involved.
The demonstration that vascular endothelial cell growth factor (VEGF) is upregulated by hypoxia
4, 5
and that levels of VEGF are increased in the retina and vitreous of patients
6-9
or laboratory animals
10, 11
with ischemic retinopathies has focused attention on VEGF as a potential mediator of retinal angiogenesis. This is supported by studies showing that VEGF antagonists partially inhibit retinal or iris NV in animal models
12-14
. There is also ample-data indicating that VEGF can stimulate NV in other tissues
15-18
.
Despite this evidence associating VEGF with retinal NV, there is conflicting data as to whether VEGF alone is sufficient to induce retinal NV. There are patients with nonproliferative diabetic retinopathy or other retinal diseases-who have elevated levels of retinal VEGF, yet no evidence of retinal NV
19-20
. In primates, multiple intravitreous injections of VEGF result in iris NV
21
and retinal vascular abnormalities including endothelial cell proliferation
23
, but do not cause definite retinal NV . Similarly, implantation of VEGF sustained release pellets into the vitreous of primates
23
or into the subretinal space of rats
34
falls to stimulate retinal NV. In rabbits; however, transient retinal NV occurs after intravitreous implantation of VEGF sustained release pellets
23
.
The basis for these conflicting data concerning the effects of VEGF in the retina compared to other tissues is unclear, but possible contributing factors may be differences in retinal vessels compared to those in other vascular beds, differences in the vascular microenvironment, such as higher levels of angiogenesis inhibitors in the retina, or difficulty in maintaining a sufficiently high level of exogenously administered VEGF in the retina. There are tight junctions between vascular endothelial cells of retina and brain, but not those of most other organs. Glia of retina and brain induce barrier characteristics to microvessels
25
, and may also act to inhibit retinal NV
26
. There are also differences between retinal and brain microvessels, with the former having a greater amount of pericyte coverage
27
and pericytes have been demonstrated to inhibit endothelial cell proliferation
28
. These differences are important because the vascular microenvironment modulates the effects of angiogenic stimuli
29
, and therefore their effects in one vascular bed may not be predictive of their effects in another.
There is a continuing need in the art for new tools to study neovascularization and ways and means to treat and prevent this major cause of blindness.
SUMMARY OF THE INVENTION
It is an object of the present invention to provide a transgenic mammal useful for studying neovascularization of the retina.
It is another object of the present invention to provide a transgenic mouse useful for developing medicinal, radiological, and gene therapies for neovascularization.
It is an object of the present invention to provide a method for screening compounds for use in treating and preventing retinopathies.
Another object of the invention is to provide a method for screening radiological and gene therapies for use in treating and preventing retinopathies.
These and other objects of the invention are achieved by providing a transgenic mammal comprising a polynucleotide encoding VEGF under the transcriptional control of a retina-specific promoter. The mammal expresses VEGF in the retina.
According to another aspect of the invention a transgenic mouse is provided. The mouse comprises a polynucleotide encoding human VEGF under the transcriptional control of a rhodopsin promoter. The mammal expresses VEGF in the retina. Intraretinal and subretinal neovascularization develops.
Another embodiment of the invention provides a method of screening test compounds as potential drugs for preventing and treating neovascularization lesions. A test compound is administered to a transgenic mammal which comprises a polynucleotide encoding VEGF under the transcriptional control of a retina-specific promoter. The mammal expresses VEGF in the retina The number or area of neovascularization lesions in the retina of the transgenic mammal is determined. A test compound which prevents or reduces the number or area of neovascularization lesions is a potential drug for preventing or treating neovascularization lesions, such as occur in disease states, including diabetes, age related macular degeneration, retinopathy of prematurity, sickle cell retinopathy.
In yet another embodiment of the invention a method of screening test therapies as potential therapies for preventing and treating neovascularization lesions is provided. A transgenic mammal is subjected to a test therapy. The mammal comprises a polynucleotide encoding VEGF under the transcriptional control of a retina-specific promoter. The mammal expresses VEGF in the retina. The number or area of neovascularization lesions in the retina of the transgenic mammal is determined. A test therapy which prevents or reduces the number or area of neovascularization lesions is a potential therapy for preventing or treating neovascularization lesions.
The present invention thus provides the art with an extremely useful model of retinal and subretinal neovascularization. The model is relatively cheap and reliable, does not require any exogenous agent, and has many characteristics of clinical intraocular neovascularization.


REFERENCES:
patent: 5332671 (1994-07-01), Ferrara et al.
Mullins et al., Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene, 1990, Nature, vol. 344, pp. 541-544.*
Taurog et al., HLA-B27 in inbred and non-inbred transgenic mice: Cell surface expression and recognition as an alloantigen in the absence of human Beta2-microglobulin, 1988, The Journal of Immunology, vol. 141, pp. 4020-4023.*
Hammer et al., Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human Beta2m: An animal model of HLA-B27-associated human disorders, 1990, Cell, vol., 63, pp. 1099-1112.*
Mullins et al., Expression of the DBA/2j Ren-2 gene in the adenal gland of transgenic mice, 1989, The EMBO Journal, vol. 8, pp. 4066-4072.*
Tobe et al., Evolution of neovascularization in mice with overexpression in vascular endothelial growth factor in photoreceptors, 1998, Investigative Opthalmology & Visual Science, vol. 39, pp. 180-188.*
Joan W. Miller, “Vascular Endothelia Growth Factor and Ocular Neovascularization” American Journal of Pathology, vol. 151, No. 1, Jul. 1997.
Naoyuki Okamoto et al. “Transgenic Mice with Increased Expression of Vascular Endothelial Growth Factor in the Retina” American Journal of Pathology, vol. 151, No. 1, Jul. 1997.
N. Okamoto et al. “Retinal Neovascularization in Transgenic MICR with Increased Expression of VEGF in the Retina” Investigative Ophthalmology & Visual Science, 1997, vol. 38, No. 4, p. S367.
Wall, Theriogeology, vol. 45, pp. 57-68.
Aszodi et al. J. Molecular Med., vol. 76, pp. 238-252.
Verma eta l. Nature, vol. 389, pp. 239-242.
Zack et al. Neuron, vol. 6, pp. 187-199.
Capecchi, Scientific American, vol. 270 pp. 34-41.

Affiliated with

Also associated with

Rating

Mouse model for ocular neovascularization does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mouse model for ocular neovascularization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mouse model for ocular neovascularization will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2916687